Lexicon Pharmaceuticals (NASDAQ:LXRX) had its target price cut by Citigroup from $15.00 to $3.00 in a research report released on Tuesday morning, BenzingaRatingsTable reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities analysts also recently weighed in on LXRX. Wedbush set a $175.00 target price on Lululemon Athletica and gave the company a hold rating in a report on Tuesday, June 11th. ValuEngine downgraded Wolverine World Wide from a hold rating to a sell rating in a report on Monday, May 20th. Zacks Investment Research upgraded HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. Stifel Nicolaus reiterated a buy rating and issued a $34.00 target price on shares of Rhythm Pharmaceuticals in a report on Monday. Finally, Needham & Company LLC upped their target price on Alteryx to $108.00 and gave the company a buy rating in a report on Thursday, May 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $12.13.
NASDAQ LXRX opened at $1.42 on Tuesday. The business’s 50-day moving average is $5.73. The firm has a market cap of $176.41 million, a P/E ratio of -1.25 and a beta of 0.84. Lexicon Pharmaceuticals has a 1 year low of $1.46 and a 1 year high of $12.17.
Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Arbitrage SA increased its holdings in shares of Lexicon Pharmaceuticals by 940.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 9,934 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 8,979 shares during the period. Wealth & Pension Services Group Inc. bought a new stake in shares of Lexicon Pharmaceuticals in the 1st quarter valued at approximately $60,000. Paloma Partners Management Co bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $73,000. Metropolitan Life Insurance Co. NY grew its stake in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 11,862 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC grew its stake in shares of Lexicon Pharmaceuticals by 67.2% in the 2nd quarter. Quantitative Systematic Strategies LLC now owns 20,648 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 8,302 shares in the last quarter. Institutional investors own 98.27% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Article: How to Invest in the Dividend Aristocrat Index
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.